MA-ROCKET-SOFTWARE
5.10.2021 15:02:11 CEST | Business Wire | Press release
Rocket Software , a global technology leader that develops enterprise software used by the world’s largest public and private sector companies, today named Milan Shetti the company’s next CEO, effective November 5. Milan will also retain his President title. Current CEO and co-founder Andy Youniss will become Executive Chairman, providing strategic insights and guidance to Rocket® in important areas where he has experience and expertise. Andy will also remain on Rocket’s Board of Directors.
“From Rocket’s creation almost 32 years ago, we set out to build a long-lasting software company that would make a difference in the world,” Youniss said. “I am incredibly proud of the company we have built, our 2,500 Rocketeers, the culture we embody, and the core values we live every day. This leadership transition is deeply important to me, and we have been intentional and thoughtful in every step of the process.”
Shetti joined Rocket in 2020 as Business Unit President and was named Rocket President earlier this year, overseeing all products in the company’s portfolio. Most recently, he held senior executive positions at Hewlett Packard Enterprise (HPE), including serving as Senior Vice President and General Manager of the multi-billion dollar storage business unit and previously as Chief Technology Officer of the Datacenter Infrastructure and Storage divisions.
“Milan is the right leader for this moment in Rocket’s history and for its future,” Youniss continued. “I have the utmost confidence that under his leadership, Rocket will continue to put our customers and partners first, deliver innovation and quality that matters, and enable even more legendary outcomes."
“I was captivated by how Rocket’s culture and technology strengthen each other,” said Shetti. “The connection Andy created between Rocket’s core values and the way we serve our customers and partners is what excites me most about leading Rocket in this next era, as we continue to accelerate the modernization of mission-critical systems and solve our customers’ and partners’ most pressing, highly technical challenges.”
“Andy has done a remarkable job building Rocket Software into a global technology leader, thoughtfully guiding the company’s growth and success. We are delighted to be able to continue working with him at the board level,” said David Humphrey, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
“Milan is an established technology leader with deep background in infrastructure management solutions. We are confident his skills and experience will enable Rocket to continue to advance its mission-critical portfolio of enterprise software solutions while furthering the commitment to its customers, employees and business partners,” added Max de Groen, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
Shetti began his career at Sun Microsystems as a software developer and advanced through a technical career path to technical director for the company’s data management group. After Sun Microsystems, Shetti led business development for IBRIX, Inc. before assuming the chief executive position. He holds a PhD in computer science from the University of Minnesota and a Master of Science in computer engineering from Syracuse University.
About Rocket Software
Rocket Software empowers organizations to create legendary impact in the world through innovation in legacy technologies. With deep expertise in IBM Z®, IBM Power®, and database and connectivity solutions, Rocket provides solutions that power tens of thousands of global businesses, solving real problems and making real-world impact. Rocket is a privately held U.S. corporation headquartered in the Boston area with centers of excellence strategically located throughout North America, Europe, Asia, and Australia. Rocket is a portfolio company of Bain Capital Private Equity.
Legacy Powers Legendary™
© 2021 Rocket Software, Inc. or its affiliates. All Rights Reserved.
Rocket® is a trademark of Rocket Software, Inc. and its subsidiaries, registered in the United States and other jurisdictions worldwide. All other trademarks cited herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005323/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom